Stężenie frakcji kostnej fosfatazy zasadowej (BALP) i zewnątrzkomórkowej domeny receptora HER-2 (ECD/HER-2) w surowicy krwi, podczas leczenia dzieci i młodzieży z mięsakiem kościopochodnym
This work is licensed under the Creative Commons Attribution 4.0 International License.
Rutkowski P, Warzocha K. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych, Mięsaki kości, 2013 rok. VM Media Sp z o.o., ISBN 9788375995947.RutkowskiPWarzochaKZalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych, Mięsaki kości2013rok. VM Media Sp z o.o., ISBN 9788375995947Search in Google Scholar
Marais L, Bertie J, Rodseth R, Sartorius B, Ferreira N. Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma 2015;4(3):80-84.MaraisLBertieJRodsethRSartoriusBFerreiraNPre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma201543808410.1016/j.jbo.2015.09.002464899726587373Search in Google Scholar
Gajewska N, Ambroszkiewicz J, Rychlowska-Pruszynska M, Laskowska-Klita T. Markers of bone formation in children with osteosarcoma. Med. Wieku Rozwoj. 2004;8:235-243.GajewskaNAmbroszkiewiczJRychlowska-PruszynskaMLaskowska-KlitaTMarkers of bone formation in children with osteosarcoma. MedWieku Rozwoj20048235243Search in Google Scholar
Ługowska I, Woźniak W, Ambroszkiewicz J, et al. Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study. Med. Wieku Rozwoj. 2009;13:201-208.ŁugowskaIWoźniakWAmbroszkiewiczJet alExtracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot studyMed. Wieku Rozwoj200913201208Search in Google Scholar
Limmahakhun S, Pothacharoen P, Theera-Umpon N, et al. Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev. 2011;12:1717-1722.LimmahakhunSPothacharoenPTheera-UmponNet alRelationships between serum biomarker levels and clinical presentation of human osteosarcomasAsian Pac J Cancer Prev20111217171722Search in Google Scholar
Sternberg RA, Pondenis HC, Yang X, et al. Association between absolute tumor burden and serum bone-specific alkaline phosphatase in canine appendicular osteosarcoma. J Vet Intern Med. 2013;27:955-963.SternbergRAPondenisHCYangXet alAssociation between absolute tumor burden and serum bone-specific alkaline phosphatase in canine appendicular osteosarcomaJ Vet Intern Med20132795596310.1111/jvim.1212123734720Search in Google Scholar
Mohamed A, Krajewski K, Cakar B. Targeted therapy for breast cancer, 2013;183(4):1096-1112.MohamedAKrajewskiKCakarBTargeted therapy for breast cancer201318341096111210.1016/j.ajpath.2013.07.00523988612Search in Google Scholar
Laudadio J, Quigley D I, Tubbs R., Wolff D J. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn. 2007;7(1):53-64.LaudadioJQuigleyD ITubbsR.WolffD JHER2 testing: a review of detection methodologies and their clinical performanceExpert Rev Mol Diagn200771536410.1586/14737159.7.1.5317187484Search in Google Scholar
Esserman LJ, Moore DH, Tsing P J, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011;129(2):607-616.EssermanLJMooreDHTsingP Jet alBiologic markers determine both the risk and the timing of recurrence in breast cancerBreast Cancer Res Treat2011129260761610.1007/s10549-011-1564-5432475021597921Search in Google Scholar
Holzer G, Pfandlsteiner T, Koschat M, Noske H, Trieb K, Kotz R. Soluble p185HER-2 in Patients With Malignant Bone Tumours. Pediatric Blood Cancer 2005;44:163-166.HolzerGPfandlsteinerTKoschatMNoskeHTriebKKotzRSoluble p185HER-2 in Patients With Malignant Bone TumoursPediatric Blood Cancer20054416316610.1002/pbc.2021715468309Search in Google Scholar
Ambroszkiewicz J, Gajewska J, Klepacka T, Chełchowska M, Laskowska-Klita T, Woźniak W. A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis. Polski Merkurisz Lekarski, 2010;29(169):19-26.AmbroszkiewiczJGajewskaJKlepackaTChełchowskaMLaskowska-KlitaTWoźniakWA comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosisPolski Merkurisz Lekarski2010291691926Search in Google Scholar
Liu PP, Leung KS, Kumta SM et al. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Oncology, 1996;53(4):275-280.LiuPPLeungKSKumtaSMet alBone-specific alkaline phosphatase in plasma as tumour marker for osteosarcomaOncology199653427528010.1159/0002275738692530Search in Google Scholar
Zhiping Y, Yanqing H, Guangzhi S et al. Measurement of bone alkaline phosphatase and relative study with osteosarcoma. Front. Med. China, 2007;1(1):54-57.ZhipingYYanqingHGuangzhiSet alMeasurement of bone alkaline phosphatase and relative study with osteosarcomaFront. Med. China200711545710.1007/s11684-007-0011-924557618Search in Google Scholar
Levine AM, Triche T, Rosenberg SA. Osteosarcoma cells in tissue culture: Characterisation and localization of alkaline phosphatase activity. Clin. Orthop. Rel. Res., 1980;146:259-268.LevineAMTricheTRosenbergSAOsteosarcoma cells in tissue culture: Characterisation and localization of alkaline phosphatase activityClin. Orthop. Rel. Res198014625926810.1097/00003086-198001000-00039Search in Google Scholar
Lim SM, Kim Y N, Park K H, Kang B, Chon H J, Kim C, Kim J H, Rha S Y. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer. 2016;16:385.LimSMKimY NParkK HKangBChonH JKimCKimJ HRhaS YBone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patientsBMC Cancer20161638510.1186/s12885-016-2415-x493272527377907Search in Google Scholar
Wasilewski-Masker K, Kastle SC, Hudson M M. et al. Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature. Pediatrics, 2008;121(3):705-713.Wasilewski-MaskerKKastleSCHudsonM M.et alBone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literaturePediatrics2008121370571310.1542/peds.2007-139618310191Search in Google Scholar
Dresner-Pollak R, Parker R A, Poku M, Thompson J, Seibel M J, Greenspan S L. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59(5):328-333.Dresner-PollakRParkerRAPokuMThompsonJSeibelMJGreenspanSLBiochemical markers of bone turnover reflect femoral bone loss in elderly womenCalcif Tissue Int199659532833310.1007/s0022399001358849397Search in Google Scholar
Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Högler W. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92(2):443-449.RauchenzaunerMSchmidAHeinz-ErianPKapelariKFalkensammerGGriesmacherAFinkenstedtGHöglerWSex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 yearsJ Clin Endocrinol Metab200792244344910.1210/jc.2006-170617105843Search in Google Scholar
Bargmann C I, Hung MC, Weinberg R A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319(6050):226-230.BargmannC IHungMCWeinbergR AThe neu oncogene encodes an epidermal growth factor receptor-related proteinNature1986319605022623010.1038/319226a03945311Search in Google Scholar
Gill J, Gellel D, Gorlick R. HER-2 Involvement in Osteosarcoma. Advances in Experimental Medicine and Biology 2014;804:161-181.GillJGellelDGorlickRHER-2 Involvement in OsteosarcomaAdvances in Experimental Medicine and Biology201480416118110.1007/978-3-319-04843-7_924924174Search in Google Scholar